Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Avecho Biotechnology Limited ( (AU:AVE) ) has issued an announcement.
Avecho Biotechnology has surpassed its recruitment target for the interim analysis of its pivotal Phase III trial of a TPM-enhanced CBD soft-gel capsule for insomnia, randomising 244 patients, 16% above plan, to strengthen statistical power. The multi-centre, double-blind, placebo-controlled study, the largest CBD insomnia trial in Australia, is progressing to an interim data read-out in June 2026 under oversight from an independent Data Monitoring Board.
The company has positioned itself for commercialisation ahead of the read-out, with Sandoz AG holding Australian rights under a 10-year licensing deal that includes upfront and milestone payments plus tiered royalties. With new patent allowances in the U.S. and Europe and an Australian OTC CBD market forecast to exceed US$125 million annually within a multi-billion-dollar global insomnia segment, a positive interim result could significantly de-risk the program and accelerate Avecho’s path to market and partnering in territories outside Australia.
More about Avecho Biotechnology Limited
Avecho Biotechnology Limited is an Australian pharmaceutical company focused on developing TPM-enhanced cannabinoid formulations, including a cannabidiol (CBD) soft-gel capsule. The company targets the insomnia and broader sleep-disorder market, aiming to register its CBD product as an over-the-counter Schedule 3 medicine in Australia and to expand into major global markets.
Average Trading Volume: 6,215,137
Technical Sentiment Signal: Sell
Current Market Cap: A$40.41M
For an in-depth examination of AVE stock, go to TipRanks’ Overview page.